Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somatuline Autogel for progressive neuroendocrine tumors
2004-002871-18Phase 2Completed
- Sponsor
- Ipsen
- Start
- Feb 2006
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lanreotide in apudoma (NET), sponsored by Ipsen. Primary endpoint: Time until disease progression. Started Feb 2006; status: completed.
02
Drugs
lanreotide
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on 2004-002871-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002871-18.